Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
We initially bought EXPE in the middle of 2022 believing company fundamentals were much stronger than market expectations suggested, and their tech and infrastructure investments would lead to business improvements. We thought competitive...
— Christina Siegel Malbon
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Expedia Group, Inc.
More institutional theses from Patient Capital Management
The manager believes Kosmos Energy's intrinsic value is three times its current market price, driven by a looming inflection in free cash flow. As capital expenditures...
Royalty Pharma offers highly defensive, diversified royalty income streams at a very low valuation of 5.9x forward earnings. Led by a...
Norwegian Cruise Line rebounded strongly in the final quarter of 2024 as robust consumer travel demand became undeniable. The fund maintained...